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During cerebellar development, Sonic hedgehog
(Shh) signaling drives the proliferation of granule
cell precursors (GCPs). Aberrant activation of Shh
signaling causes overproliferation of GCPs, leading
to medulloblastoma. Although the Shh-binding pro-
tein Boc associates with the Shh receptor Ptch1 to
mediate Shh signaling, whether Boc plays a role in
medulloblastoma is unknown. Here, we show that
BOC is upregulated in medulloblastomas and in-
duces GCP proliferation. Conversely, Boc inactiva-
tion reduces proliferation and progression of early
medulloblastomas to advanced tumors. Mechanis-
tically, we find that Boc, through elevated Shh
signaling, promotes high levels of DNA damage, an
effect mediated by CyclinD1. High DNA damage in
the presence of Boc increases the incidence of
Ptch1 loss of heterozygosity, an important event in
the progression from early to advancedmedulloblas-
toma. Together, our results indicate that DNA dam-
age promoted by Boc leads to the demise of its
own coreceptor, Ptch1, and consequently medullo-
blastoma progression.
INTRODUCTION
The Hedgehog (Hh) signaling pathway is crucial for embryonic
development, adult tissue homeostasis, and tumorigenesis (Bar-
akat et al., 2010). SonicHedgehog (Shh) functionsbybinding to its
receptor Patched1 (Ptch1), relieving the inhibition of Smoothened
(Smo) activity.Once active, Smo induces a downstreamsignaling
cascade that results in the activation of Gli transcription factors.34 Developmental Cell 31, 34–47, October 13, 2014 ª2014 Elsevier IWe recently identified that in addition to the Shh receptor
Ptch1, at least one coreceptor (Boc, Cdon, or Gas1) is required
to form a functional Shh reception complex with Ptch1 and
mediate Shh signaling (Allen et al., 2011; Izzi et al., 2011). These
coreceptors have overlapping but distinct expression patterns,
explaining their redundant role in some tissues but not others
(Allen et al., 2011; Izzi et al., 2011; Okada et al., 2006; Tenzen
et al., 2006; Zhang et al., 2006).
Maintained or overactivation of the Shh signaling pathway can
lead to cancer. One cancer that can result from overactivation of
the Shh signaling pathway is medulloblastoma (MB). During
cerebellar development, Shh secreted from Purkinje cells acti-
vates Shh signaling in granule cell precursors (GCPs) and drives
their proliferation. Activating mutations of the Shh signaling
pathway causes overproliferation of GCPs, which leads to MB,
a cerebellum tumor mostly found in children. MB is the most
common malignant brain tumor in childhood and ranks among
the leading causes of cancer-related mortality in this age group.
Here, we report that the expression of the Shh receptorBOC is
highly upregulated in the SHH subgroup of humanMBs. This up-
regulation is also observed in mouse models of MB, where we
show that Boc expression is high in early preneoplasia and
maintained in advanced MBs. Furthermore, upregulation of
Boc in GCPs—the cells of origin for this subgroup of MB (Schu¨l-
ler et al., 2008; Yang et al., 2008)—increased their proliferation.
Conversely, Boc inactivation decreased the size of MBs and
reduced the progression of early MB into advanced tumors.
We find that Boc regulates tumor size by controlling the prolifer-
ation rate of early tumor cells through the expression of genes
important for cell proliferation, such as CyclinD1 and N-Myc. In
addition, we show that Boc, through elevated Shh signaling,
promotes high levels of DNA damage, an effect mediated by Cy-
clinD1. Importantly, inactivating Boc reduces DNA damage and
the incidence of Ptch1 loss of heterozygosity (LOH), a critical
event that controls the progression of early MB into advanced
MB. Thus, our data indicate that Boc is important for the earlync.
AB
O
C
 lo
g 2
 e
xp
re
ss
io
n 
ra
tio
  
(tu
m
or
/n
or
m
al
 c
er
eb
el
lu
m
) 
WNT SHH Group 3 Group 4 
3 
2 
1 
0 
-1 
-2 
Medulloblastoma subgroup
p < 0.0001 
Medulloblastoma
subgroup
n Gain of 3q13.2 
locus (%) 
WNT 5 0 (0) 
SHH 26 7 (27) 
Group 3 21 0 (0) 
Group 4 29 0 (0) 
Gain of 3q13.2 locus analysis  
(500K SNP array) 
C 
BOC
BOC
BOC
SHH (n=26)
WNT (n=5)
*** 
BOC
Group 4 (n=29)
Group 3 (n=21)
D BOC
Chr3 centromeric probe
Heidelberg 
B 
WNT SHH Group 3 Group 4 
3 
2 
1 
0 
-1 
-2 B
O
C
 lo
g 2
 e
xp
re
ss
io
n 
ra
tio
  
(tu
m
or
/n
or
m
al
 c
er
eb
el
lu
m
) 
Medulloblastoma subgroup
p<0.0001 Toronto 
Figure 1. BOC Expression Is Upregulated in
Human MBs of the SHH Subgroup
(A) Box plot of BOC mRNA expression in a cohort
of 64 human MBs (Heidelberg) classified accord-
ing to their subgroup. Data are presented as log2 of
the ratio of BOC expression in tumors over normal
cerebellum.
(B) Analysis similar to (A) performed on our Toronto
cohort (103 MBs).
(C) 500K single-nucleotide polymorphism (SNP)
array showing gain of locus 3q13.2 that includes
the BOC gene in a cohort of 81 human MBs (Tor-
onto cohort). This gain was found exclusively in the
SHH subgroup. Red bars above chromosomal loci
represent gained regions.
(D) Fluorescence in situ hybridization (FISH) anal-
ysis for the BOC gene (green) in a SHH subgroup
MB tumor from a Li-Fraumeni patient. The tumor
presents an amplification of the BOC gene while a
chromosome 3 centromeric probe (red) shows a
normal complement. Kruskal-Wallis test (A and B)
and Fisher’s exact test (C) were performed.
See also Figure S1.
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Boc Promotes Medulloblastoma Progressionsteps of MB tumorigenesis by promoting the loss of its core-
ceptor Ptch1. Furthermore, we show that inactivating Boc
helps to prevent MB progression and related lethality, demon-
strating that the targeting of tissue-restricted components of
the Shh signaling pathway, such as Boc, can prevent cancer
development.
RESULTS
BOC Expression Is Highly Upregulated in a Subset
of Human MBs
To investigate whether BOC has a role in MB tumorigenesis, we
first analyzed the expression of BOC in a cohort of 64 humanMB
tumors (Remke et al., 2011). Gene expression profiling studies
have identified four subgroups of MB: WNT, SHH, group 3,
and group 4 (Taylor et al., 2012). The WNT and SHH subgroups
are characterized by activation of the WNT and the SHH
signaling pathway, respectively. BOC expression was strongly
upregulated in the SHH subgroup (BOC log2 > 0) compared to
normal cerebellum, and to a lesser extent in the WNT subgroup,
while subgroups 3 and 4 did not show upregulation of BOC (Fig-
ure 1A). Analysis of BOC expression in a second, independent
cohort of 103 human MB tumors (Northcott et al., 2011) gave
virtually identical results (Figure 1B). Further analysis indicatedDevelopmental Cell 31, 34–47that highBOC expressionwas associated
with desmoplastic histology, nonmeta-
static disease, and chromosome 17
balanced tumors, all of which are features
of MBs of the SHH type (Figure S1 avail-
able online and data not shown).
Of interest, comparative genomic hy-
bridization analysis of our human MB
cohort indicated that 7 out of 81 tumors
(9%) had a 3q13.2 gain, a chromosomal
region encompassing the BOC gene (Fig-
ure 1C). Remarkably, all of the tumorswith a gain in this region belonged to the SHH subgroup so
that, overall, 27% (7/26) of the tumors of the SHH subgroup
had a 3q13.2 gain. Patients with Li-Fraumeni syndrome harbor
a TP53 germline mutation and develop MB of the SHH group
(Rausch et al., 2012). Genomic sequencing of MBs from these
patients suggested that a focal chromosomal region containing
the BOC gene can also be amplified in these tumors (Rausch
et al., 2012). To confirm that BOC is amplified in a subset of
MB tumors of the SHH subgroup, we performed fluorescence
in situ hybridization (FISH) for BOC in tumor cells from a Li-Frau-
meni patient (Figure 1D). A high level amplification of BOC was
observed in these tumor cells, compared to a centromeric con-
trol probe detecting the same chromosome. Thus in human SHH
subgroup MB, the expression of BOC is upregulated and in a
subset of these tumors, the gene is also amplified.
Boc Expression Is Upregulated in Shh Pathway-
Dependent Mouse MBs
Because BOC expression is upregulated in the SHH subgroup
of human MB, we examined whether Boc expression is also
elevated in Shh pathway-dependent mouse models of MB.
Mice heterozygous for a mutation in the Shh receptor Ptch1
gene develop spontaneous MB (Goodrich et al., 1997). A com-
parison of the gene expression profile of tumor tissue isolated, October 13, 2014 ª2014 Elsevier Inc. 35
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belong to the Shh subgroup, as exemplified by the upregulation
of Gli1, a Shh pathway transcriptional target (Figure 2A) (Gibson
et al., 2010; Oliver et al., 2005). Consistent with what we
observed in our two human cohorts, Boc expression was also
highly upregulated in this same set of mouse tumors (Figure 2A).
We verified these mRNA expression profiles by performing
quantitative RT-PCR on our independent mouse tumor samples
and confirmed that BocmRNA expression is highly upregulated
in Ptch1+/MB compared to normal cerebellum (Figure 2B). Boc
immunostaining on MB sections from Ptch1+/ mice revealed
that, in addition to Boc mRNA, the Boc protein is strongly ex-
pressed in MBs compared to adjacent normal cerebellum and
brain tissue (Figure 2D). To further confirm this, we examined
Boc levels in a second MB mouse model (Schu¨ller et al., 2008).
In this model, Math1-Cre mice, which express the Cre recombi-
nase specifically in GCPs, are crossed with mice harboring a
conditionally-expressed, constitutively active Smo (SmoM2)
allele. Mice generated from these crosses develop aggressive
cerebellar tumors and most die within 2 month of age. Similarly
to what we observed in Ptch1+/ tumors, Math1-Cre; SmoM2
MB exhibit highly elevated Boc levels compared to normal tissue
(Figure 2D). We have previously reported that the Boc homolog
Cdon is not expressed in the developing nor adult cerebellum
(Izzi et al., 2011). Immunostainings on Ptch1+/ MB sections
also failed to detect Cdon, indicating that it is not expressed in
MBs (Figure 2C), consistent with the mRNA expression data
(Figure 2A). Together, these results indicate that Boc is highly
upregulated at the mRNA and protein levels in MBs of the Shh
subgroup.
Elevated Boc Levels Induce GCP Proliferation
Because we had previously shown that Boc inactivation reduces
GCP proliferation in response to Shh (Izzi et al., 2011), we hy-
pothesized that the elevated BOC expression that occurs in
MBs might drive the proliferation of MB. To test this possibility,
we purified mouse GCPs and infected them with a retrovirus ex-
pressing BOC to test whether increased BOC expression affects
GCP proliferation. Elevating BOC levels induced GCP prolifera-
tion, as measured by the percentage of infected clones that
proliferated after 2.5 days (Figure 2E). Treatment of BOC-ex-
pressing GCPs with SANT-1, a Smo antagonist, or GANT-58, a
Gli inhibitor, abrogated their proliferation to levels similar to those
of control cells, indicating that this effect of BOC requires Smo
and Gli activity (Figures 2E and S2A). As expected, the prolifera-
tive effect of BOC was further potentiated by the addition of Shh
(Figure 2E). Similar trends (although quantitatively different) were
obtained when a shorter time course for Boc expression was
used (20 hr; Figure 2I).
Shh signaling controls GCP proliferation through the regula-
tion of N-Myc and CyclinD1 expression (Browd et al., 2006; Hat-
ton et al., 2006; Kenney et al., 2003; Kenney and Rowitch, 2000;
Kessler et al., 2009; Oliver et al., 2003; Swartling et al., 2010). To
understand how BOC mediates this proliferative effect, we as-
sessed the effect of BOC overexpression in GCPs on the expres-
sion of the Shh pathway target genesCyclinD1,N-Myc, andGli1.
As expected, ShhN induced the expression of these genes (Fig-
ures 2F–2H). Overexpression of BOC alone had no effect on
these Shh targets; however, when we overexpressed BOC in36 Developmental Cell 31, 34–47, October 13, 2014 ª2014 Elsevier Ithe presence of ShhN, this further increased expression of Cy-
clinD1, N-Myc, and Gli1. Thus, although BOC overexpression
has a modest effect on proliferation in the absence of Shh, in
the presence of Shh, its activity is highly potentiated, increasing
proliferation and CyclinD1, N-Myc, and Gli1 expression. Taken
together, these results indicate that high levels of BOC enhance
Shh signaling and Shh-dependent GCP proliferation.
Boc Inactivation Decreases the Incidence of MB
Because Boc drives proliferation of GCPs, we then tested
whether Boc inactivation could reduce MB incidence. We exam-
ined theMB incidence in Ptch1+/mice where the Boc gene was
inactivated. The MB incidence in Ptch1+/ mice varies with the
genetic background. After backcrossing the Ptch1+/ mice in a
C57Bl6 background for over six generations, we routinely
observe that 55% of the mice develop MB and die from it,
mostly around 3–6 months of age (Figure 3A). This incidence is
similar to what some other groups have observed with this strain
of Ptch1mice (see Experimental Procedures). Using this model,
we generated mice in which the Boc gene was inactivated in
combination with Ptch1+/, and we assessed the incidence of
lethality caused by MB over 1 year. In each case, we confirmed
that lethality was caused by the presence of an advancedMB. As
expected, survival analysis indicated that Boc+/;Ptch1+/+ and
Boc/;Ptch1+/+ mice do not develop MB (Figure 3A). Remark-
ably, while control Boc+/+;Ptch1+/ and Boc+/;Ptch1+/ mice
developed lethal MB with an incidence of 55% (similar to
Ptch1+/ mice), Boc/;Ptch1+/ mice developed significantly
fewer MB, with an incidence of only 20% (p < 0.05). Impor-
tantly, Boc inhibition did not simply lead to a delay in the devel-
opment of MB, as the survival curve remained stable with no new
cases of MB occurring after 5 months of age. Thus, deletion of
the Boc gene prevented the development of advanced MB
(and the associated death) in two-thirds of the Ptch1+/ mice
that would normally have developed a lethal MB. This indicates
that Boc is important for MB tumorigenesis.
High Boc Expression Is Associated with the Early Steps
of MB Tumorigenesis
We next investigated at which step of MB tumorigenesis Boc
plays a role. During cerebellum development, Shh secreted by
Purkinje cells (PC) induces the proliferation of GCPs located in
the external germinal layer (EGL). When they cease proliferating,
granule cellsmigrate through the PC layer and populate the inter-
nal granular layer (IGL). MB development is a multistep process
that begins with overproliferation of GCPs at early stages of cer-
ebellum development and their persistence on the surface of the
cerebellum (Kim et al., 2003; Oliver et al., 2005). These groups of
cells are called preneoplasia. The progression of these preneo-
plasia into advanced MBs requires additional genetic events;
the most characterized being the loss of the second allele of
Ptch1, or Ptch1 loss of heterozygosity (LOH) (Berman et al.,
2002; Oliver et al., 2005; Pazzaglia et al., 2006; Uziel et al.,
2005). Thus, preneoplasia are lesions where Ptch1 LOH has
not occurred yet. Conversely, advanced MBs have lost Ptch1.
As Ptch1 LOH does not happen at the same time in all mice,
the Ptch1 status of early tumors (%4 weeks) can vary as some
of them will be preneoplastic and some others will have Ptch1
LOH and progressed to advanced MBs. Thus, for clarity, wenc.
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Figure 2. Boc Expression Is Upregulated in Shh Pathway-Dependent MouseMBs, and Elevated Boc Expression Increases GCP Proliferation
(A) RelativeGli1,Boc, andCdonmRNA levels in normal P7GCPs orPtch1+/MB. Data were extracted fromGSE24628 gene expressionmicroarray (Gibson et al.,
2010).
(B) Relative Boc mRNA levels in cortex, normal cerebellum or MB in the Ptch1+/ mouse model, measured by qRT-PCR. Transcript levels were normalized to
Hprt1.
(C and D) Sections of mouse MBs immunostained with anti-Cdon and anti-Boc antibodies, visualized with DAB (brown) and counterstained with hematoxylin
(blue). (C) Cdon is absent from adult Ptch1+/ MB. (D) Boc is highly expressed in adult Ptch1+/ MB (left) and P20 Math1-Cre;SmoM2 MB (right). Scale bars
represent 2 mm (top panels) and 50 mm (bottom panels). Cb, cerebellum.
(E) Mouse GCPs were infected with a retrovirus expressing either BOC or a control (Ctl), and incubated with 134 nM SANT-1 (SANT) or 3 nM ShhN for 2.5 days.
Infection was detected by PLAP activity. Proliferation of infected GCPs was measured by counting cell numbers in each PLAP positive clone. Two or more cells
per clone indicated a proliferating clone. Two-way ANOVA with Bonferroni posttests were performed.
(F–I) Mouse GCPs were electroporated with plasmids expressing either Boc fused to GFP (Boc) or GFP alone (Ctl) and cultured 20 hr in absence or presence of
10 nM ShhN before qRT-PCR analysis. Boc increases expression of CyclinD1, N-Myc, Gli1, and Ki67 only in the presence of ShhN.
Error bars represent SEM. See also Figure S2.
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Figure 3. Boc Inactivation Decreases MB Incidence and Progression of Early MB into Advanced Tumors
(A) Kaplan-Meier survival curves comparing mice with two (Boc+/+;Ptch1+/; n = 41), one (Boc+/;Ptch1+/; n = 35), or no (Boc/;Ptch1+/; n = 21) Boc alleles,
followed over 1 year. Control mice:Boc+/;Ptch1+/+ (n = 41) andBoc/;Ptch1+/+ (n = 27). The presence of aMBwas detected in all mice that died. Entire cerebella
were fixed and sectioned to confirm absence of MB in all mice that survived. Log-rank (Mantel-Cox) tests were performed.
(B) High Boc expression is associated with the early steps of MB tumorigenesis. Cerebellum sagittal sections of P2, P7, P14, and P21 Ptch1+/+ and Ptch1+/mice
were immunostained with anti-Boc antibody, visualized with DAB (brown), and counterstained with hematoxylin (blue). Scale bar represents 100 mm.
(C–E) Boc controls MB size and progression. (C) Top: representative MB lesions for each size group at P14. Bottom: number of cerebellum lesions and their
relative frequencies according to size in Boc+/+;Ptch1+/ (9 mice; 24 lesions) and Boc/;Ptch1+/ (7 mice; 21 lesions) mice at P14. (D) Number of cerebellum
lesions and their relative frequencies according to size in Boc+/+;Ptch1+/ (11 mice; 36 lesions) and Boc/;Ptch1+/ (7 mice; 30 lesions) mice at P22. (E) MB
(legend continued on next page)
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Boc Promotes Medulloblastoma Progressionwill refer to %4 weeks lesions for which the Ptch1 status is un-
known as ‘‘early MBs’’ and use ‘‘preneoplasia’’ only in the cases
where we have assessed the Ptch1 status. Preneoplasia that do
not progress to advanced tumors eventually regress and disap-
pear (Corcoran et al., 2008; Kessler et al., 2009; Kim et al., 2003;
Pazzaglia et al., 2006).
To test whether Boc expression is associated with the early
steps of MB tumorigenesis, we analyzed MB progression in
Ptch1+/mice at four different developmental stages (Figure 3B).
At postnatal day 2 (P2) and P7, we observed that Boc protein is
mostly found in the EGL of the cerebellum, where proliferating
GCPs are located. At P14, in WT Ptch1+/+ mice, the majority of
GCPs have migrated through the PC layer, to the IGL, and very
few GCPs remain in the very thin EGL. However, in Ptch1+/
mice we could observe early MBs, as evidenced by the persis-
tence of GCPs in the EGL. These cells were highly positive for
Boc. At P21, all GCPs have migrated out of the EGL in WT
mice. However, persistent GCPs forming early MB still remain
in the EGL of Ptch1+/mice. These cells were also highly positive
for Boc. Together, these results indicate that, in addition to being
highly expressed in advanced tumors (Figures 2A, 2B, and 2D),
Boc is also expressed at high levels in early MBs.
Boc Is Important for the Progression of Early MB into
Advanced Tumors
We next investigated whether Boc acts in the formation of early
MBs and/or their progression into advanced tumors. We started
by characterizing MB tumorigenesis in Boc/;Ptch1+/ and
Boc+/+;Ptch1+/mice at P14, the earliest stage at which tumori-
genic lesions can be distinctly observed.We did not detect a sig-
nificant difference in the number of lesions per cerebellum be-
tween the two genotypes, indicating that Boc does not regulate
the transition from normal GCPs to preneoplasia (Figure 3C).
However, when we compared the size of these lesions, we
observed that Boc inactivation reduced the average tumor area
15-fold. The frequency distribution of the tumor size revealed
that in Boc+/+;Ptch1+/mice 12.5% of the lesions were relatively
large (>5 mm2), while Boc/;Ptch1+/mice did not have any le-
sions of that size (Figure 3C). Conversely, in Boc/;Ptch1+/
mice, 76% of the lesions were very small (<0.4 mm2), compared
toonly 55% inBoc+/+;Ptch1+/mice. Similar trendswere also ob-
tained when the analysis was performed at P22: while Boc inac-
tivation did not affect the number of lesions per cerebellum, it
reduced the average tumor area (Figure 3D). The relative fre-
quency of the tumor sizes revealed that most of the lesions
(53%) in Boc/;Ptch1+/ mice were smaller than 0.4 mm2,
compared toonly 25% inBoc+/+;Ptch1+/mice, andmore lesions
had progressed to larger sizes (1–5 and >5 mm2) in Boc+/+;
Ptch1+/mice compared to Boc/;Ptch1+/mice.
We next analyzed the role of Boc in tumor progression and
regression by examining mice at 8 weeks, a stage where most
of the preneoplasia have either regressed or progressed to
neoplasia (Pazzaglia et al., 2006). Similarly to what we observed
at P14 and P22, tumor area was significantly smaller in Boc/;lesions at 8 weeks of age are smaller in Boc/;Ptch1+/ (n = 16) than Boc+/+;P
Boc+/+;Ptch1+/ and Boc/;Ptch1+/mice. Mann-Whitney tests were performed
indicate MB lesions. EGL, external germinal layer; ML, molecular layer; PC, Purk
Error bars represent SEM.
DevePtch1+/ mice than in Boc+/+;Ptch1+/ mice (Figure 3E). Upon
inspection of the relative frequency of the tumor size, we
found that Boc/;Ptch1+/mice had more lesions in regression
and/or that disappeared (56% of them are <1.5 mm2) than
Boc+/+;Ptch1+/ mice, which had only 25% of their lesions in
regression or disappeared. In addition, Boc+/+;Ptch1+/ mice
had many more large tumors (50% of the lesions were
>10.5 mm2) than Boc/;Ptch1+/ mice, where only 19% of the
lesions were >10.5 mm2 (Figure 3E). Remarkably, these values
are very similar to the percentage of mice that eventually develop
advanced MB: 59% for the Boc+/+;Ptch1+/ mice and only 21%
for the Boc/;Ptch1+/ mice (Figure 3A). This suggests that the
large lesions (>10.5 mm2) observed at 8 weeks are neoplastic tu-
mors that progressed to advanced MB and will cause lethality.
Conversely, it also suggests that the small lesions (<1.5 mm2)
will not progress to advanced tumors.
Taken together, our results indicate that while Boc is not
involved in preneoplasia initiation, it is important for tumor
growth and progression into advanced MB.
Boc Drives Tumor Cell Proliferation and the Expression
of Proliferative Oncogenes in Early MB
Wenext investigated themechanismbywhich Boc controls tumor
growthandprogression toadvancedMB.First,we immunostained
P14 lesions to determinewhether early tumor cells highly express-
ing Boc showed elevated Shh pathway activity. We used expres-
sion of the nuclear b-gal (inserted in the Ptch1 locus) as a marker
for Shh pathway activity, because Ptch1 is a direct transcriptional
target of the Shh pathway. The majority of the cells with elevated
Boc expression also had strong b-gal expression (yellow arrows),
while zones with lower Boc tended to have little, if any, b-gal
expression (Figure4A, red arrows). Thus, highBocexpression cor-
relates with high activation of the Shh signaling pathway.
We also verified whether early tumor cells expressing high
levels of Boc also had high levels of proliferation. Immunostain-
ing of P14 lesions showed a high correlation between Boc+ cells
and Ki67+ cells (Figure 4B, yellow arrows). Conversely, regions of
low Boc expression (red arrows) were devoid of Ki67. These re-
sults indicate that in early MBs, high Boc expression correlates
with high activation of the Shh signaling pathway and with high
levels of proliferation.
We next investigated the consequences of inactivating Boc on
Shh signaling and early MB cell proliferation. We quantified Gli1
mRNA levels in cells from early MB and found that Gli1 mRNA
levels were reduced 2-fold in Boc/;Ptch1+/ compared to
Boc+/+;Ptch1+/ mice (Figure 4C). Similarly, Ki67 mRNA and
Ki67+ cells were reduced 2-fold in Boc/;Ptch1+/ compared to
Boc+/+;Ptch1+/ mice (Figures 4D and 4E), consistent with a
decrease in Shh-mediated proliferation. Thus, Boc modulates
ShhpathwayactivityandproliferationofearlyMBcells. Incontrast,
weobservednoeffect of deletingBoconapoptosis or on the regu-
lation of the antiapoptotic gene Bcl2 (Figures 4F and 4G).
AsShh signaling controls proliferation, at least partially, through
the regulation of the expression of CyclinD1 (Kenney et al., 2003;tch1+/ mice (n = 12). Relative frequencies of tumor area per cerebellum of
(C–E). Scale bars represent 400 mm (C and E). Arrows and dashed lines (yellow)
inje cells; IGL, internal granular layer.
lopmental Cell 31, 34–47, October 13, 2014 ª2014 Elsevier Inc. 39
AB
C D E H
F
G
I J
Figure 4. Boc Drives Shh Signaling and Proliferation in Early MB
(A and B) Sections of earlyMBs fromP14Ptch1+/(ßgal)mice coimmunostainedwith anti-Boc and either anti-b-galactosidase (b-gal) (A) or anti-Ki67 (B) antibodies.
Nuclear b-gal expression from the Ptch1 locus is a marker for Shh signaling activity because Ptch1 is a direct transcriptional target of the Shh pathway. Note that
the b-gal allele is denoted in (A) and (B) for clarity but is omitted in other figures for simplicity. Cells expressing high levels of Boc are positive for b-gal (A) and the
(legend continued on next page)
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Boc Promotes Medulloblastoma ProgressionKenneyandRowitch,2000) andN-Myc (Browdetal., 2006;Hatton
et al., 2006; Kenney et al., 2003; Kessler et al., 2009; Oliver et al.,
2003; Swartling et al., 2010), two targets of the Shh signaling
pathway, we tested whether CyclinD1 and N-Myc expression
was affected in Boc/;Ptch1+/ early tumors. We found that
CyclinD1 and N-Myc mRNA levels in early MB cells were lower
in Boc/;Ptch1+/ compared to Boc+/+;Ptch1+/ mice (Figures
4H and 4J). Consistent with the decrease in CyclinD1 mRNA
levels, we also found thatBoc inactivation reduced CyclinD1 pro-
tein levels in early MB (Figure 4I). Taken together, these results
indicate that Boc inactivation significantly decreases early MB
cell proliferation and this might be due to a decrease in CyclinD1
and N-Myc expression.
Because this analysis of the role of Boc on gene expression in
early MB might be confounded by a difference in the number of
tumors with Ptch1 LOH versus tumors without Ptch1 LOH, we
also assessed the Ptch1 LOH status in these early tumors. For
this, we used an exon-specific RT-PCR approach to detect
expression of the WT Ptch1 allele (but not the Ptch1 targeted
allele). We then removed the early tumors harboring Ptch1
LOH from our analysis and compared gene expression only in
early tumors from Boc/;Ptch1+/ and Boc+/+;Ptch1+/ animals
wherePtch1 LOHwas not present, i.e., we assessed the effect of
Boc on gene expression only in preneoplasia. Similarly to the
analysis we performed in early tumors (Figures 4C, 4D, 4H,
and 4J), this analysis showed that Boc regulates the expression
of Gli1, Ki67, CyclinD1, and N-Myc in preneoplasia (Figure S3).
Boc Is Required for Shh-Induced DNA Damage
Oncogene-induced DNA replication stress is an important
mechanism leading to the acquisition of DNA damage and
consequently mutations necessary for cancers to progress
from a preneoplastic stage to an advanced stage (Bartkova
et al., 2005; Gorgoulis et al., 2005). Our data showing that Boc
regulates the levels of CyclinD1, an oncogene capable of pro-
moting replication stress (Aggarwal et al., 2007) lead us to hy-
pothesize that the presence of Boc might be associated with
increased DNA damage.
To quantify levels of DNA damage, we directly measured the
amount of fragmented DNA in a cell using comet assays. We
also quantified the number of cells with DNA breaks by immuno-
staining for g-H2AX (phosphoserine 139), a marker of DNA
breaks. Using the comet assay, we found that Shh increases
DNA fragmentation of WT GCPs, as visualized by an increase in
the amount of fragmented DNA in the comet tail (Figure 5A) and
asmeasured by an increase in the comet tail moment (Figure 5B).
In contrast, Shh stimulation of Boc/ GCPs had no effect onproliferation marker Ki67 (B) (yellow arrows) while cells not expressing or expressin
represent 30 mm (A and B, bottom two panels) 200 mm (B, top panel).
(C–E) Boc drives expression ofGli1 and cell proliferation in early MB. (C)Gli1 and (
and Boc/;Ptch1+/ (n = 9) cerebella. (E) Relative number of proliferating cell
normalized to tumor surface area.
(F and G) Boc does not regulate apoptosis in early MB. (F) Bcl2 mRNA levels in
(n = 9). (G) Relative number of cells positive for active caspase-3 in 4 week Boc+
(H–J) Boc drives expression of N-Myc and CyclinD1 in early MB. (H) CyclinD1 an
(n = 7) and Boc/;Ptch1+/ (n = 9) cerebella. Transcript levels were normaliz
mice immunostained with anti-CyclinD1. Early lesions expressing Boc (Boc+/+;P
(Boc/;Ptch1+/; n = 7). Unpaired t tests were performed (C–J). Scale bar repre
Error bars represent SEM.
DeveDNA fragmentation (Figures 5A and 5B). Hence, Boc is required
for the Shh-induced DNA damage that we observe in GCPs.
To confirm that the effect of Shh onDNA damage is dependent
on Shh-induced proliferation, we found that in the absence of
proliferation, Boc+/+ and Boc/ GCPs have the same levels of
DNA damage (Figures S4A and S4B). Thus, proliferation is
required for Boc to promote DNA damage. To confirm that
the requirement of Boc to promote DNA damage is ligand-
dependent, we assessed the levels of DNA damage in GCPs
harboring a constitutively active Smo (Math1-Cre;SmoM2)
where Shh signaling and proliferation are ligand-independent.
Because Smo functions downstream of Boc, removing Boc
from SmoM2 GCPs should have no effect on DNA damage. As
anticipated, knockdown of Boc in SmoM2 GCPs did not signifi-
cantly change the level of DNA damage (Figures S4C and S4D).
Together, these results are consistent with Boc-dependent DNA
damage being Shh ligand-dependent.
We next measured the amount of DNA damage in Ptch1+/
GCPs, which have higher levels of Shh signaling than Ptch1+/+
GCPs. We found that the amount of DNA fragmentation (Figures
5C and 5D) and number of g-H2AX positive cells (Figure 5E) was
higher in Ptch1+/ compared to Ptch1+/+ cells, indicating that
a higher level of Shh signaling is associated with more DNA
damage. Notably, when Boc is absent from Ptch1+/ GCPs,
the amount of DNA damage in response to Shh was markedly
reduced, with a 5-fold lower number of g-H2AX positive cells
(Figure 5F), consistent with Boc being required for Shh-induced
DNA damage in both WT and Ptch1+/ GCPs.
CyclinD1 Is Essential for Shh-Induced DNA Damage
Because Boc, through Shh signaling, regulates the levels of
CyclinD1, a gene capable of promoting replication stress in other
cell types (Aggarwal et al., 2007), we hypothesized that CyclinD1
might be required for the increased DNA damage in response to
Shh signaling. In WT GCPs, activating Shh signaling with Shh
ligand increases the number of g-H2AX positive cells (Figure 5G).
WhenCyclinD1 is absent, theeffect ofShhong-H2AXpositivecell
number is lost, indicating that CyclinD1 is essential for this Shh-
dependent increase in DNA damage. Similarly, direct measure-
ment of DNA damage using comet assays indicated that, while
Shh induces DNA fragmentation in WT GCPs, Shh stimulation
of CyclinD1/ GCPs had no significant effect on DNA damage
(Figures 5H and 5I). Thus, similarly to Boc, CyclinD1 is required
for Shh-induced DNA damage, and the absence of either Boc
or CyclinD1 totally abrogates the effect of Shh on DNA damage.
Given that Boc regulates CyclinD1 levels, these results suggest
that Boc promotes DNA damage through CyclinD1.g very low levels of Boc are negative for b-gal and Ki67 (red arrows). Scale bars
D) Ki67mRNA levels in tumor cells purified from 4 week Boc+/+;Ptch1+/ (n = 7)
s (Ki67+) in lesions from Boc+/+;Ptch1+/ and Boc/;Ptch1+/ mice at P14,
tumor cells isolated from 4 week Boc+/+;Ptch1+/ (n = 7) and Boc/;Ptch1+/
/+;Ptch1+/ (n = 9) and Boc/;Ptch1+/ (n = 6) tumor cells.
d (J) N-Myc mRNA levels in tumor cells purified from 4 week Boc+/+;Ptch1+/
ed to Gusb (C, D, F, H, and J). (I) Sections of early MB from P14 Ptch1+/
tch1+/; n = 7) have higher levels of CyclinD1 than lesions not expressing Boc
sents 30 mm (I).
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Figure 5. Boc and CyclinD1 Are Required for Shh-Induced DNA Damage
(A) Representative images of comet assays showing that Shh induces DNA fragmentation in Boc+/+ GCPs but not in Boc/ GCPs.
(B) Relative tail moment measured from the comet assays of Boc+/+ and Boc/ GCPs cultured in the absence or presence of 10 nM ShhN.
(C) Representative images from comet assays showing that Ptch1+/GCPs have more DNA fragmentation than Ptch1+/+GCPs. GCPs were cultured with 10 nM
ShhN.
(D) Relative tail moment in Ptch1+/+ and Ptch1+/ GCPs cultured with 10 nM ShhN.
(E) Representative images and relative number of g-H2AX positive cells in Ptch1+/+ and Ptch1+/ GCPs cultured with 10 nM ShhN. Scale bar represents 10 mm.
(F) Representative images and relative number of g-H2AX-positive Boc+/+;Ptch1+/ and Boc/;Ptch1+/GCPs cultured with 10 nM ShhN. Scale bar represents
5 mm.
(G–I) Shh induces DNA damage in CyclinD1+/+ but not in CyclinD1/GCPs. (G) Representative images and relative number of g-H2AX positive CyclinD1+/+ and
CyclinD1/GCPs cultured in the absence or presence of 10 nM ShhN. (H) Representative images of comet assays and (I) relative tail moment from CyclinD1+/+
and CyclinD1/ GCPs cultured in the absence or presence of 10 nM ShhN. GCPs were isolated from the cerebella of P5-P7 mice for all experiments. Mann-
Whitney tests (D), t tests (E and F), two-way ANOVA (G), and Kruskal-Wallis tests (B and I) were performed. Scale bar represents 10 mm (G).
Error bars represent SEM. See also Figures S3 and S4.
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Figure 6. Boc Promotes Ptch1 Loss of Heterozygosity in Preneoplasia, Promoting MB Progression into Advanced Tumors
(A and B) Incidence of Ptch1 LOH in early (4 week) (A) or advanced (B) MBs from Boc+/+;Ptch1+/ and Boc/;Ptch1+/mice. mRNA from MB was subjected to
qRT-PCR using specific primers within exons 2–3 of Ptch1 (Oliver et al., 2005). Amplification of sequences with exons 2–3 primers indicates the presence of the
WT allele (Ptch1 retention) whereas the absence of amplification indicates loss of the WT Ptch1 allele (Ptch1 LOH). Boc promotes LOH of the Ptch1 WT allele.
(C and D) N-Myc and CyclinD1 expression do not depend on Boc after Ptch1 LOH in advanced MB. Transcript levels were normalized to Gusb (A–D).
(E) Inactivation of Boc in MBs with constitutive Smo activity does not decrease tumor growth. Kaplan-Meier survival curves comparing mice with constitutively
active Smo (SmoM2) in GCPs with two (Math1-cre;SmoM2;Boc+/+; n = 26), one (Math1-cre;SmoM2;Boc+/; n = 21), or no (Math1-cre;SmoM2;Boc/; n = 5) Boc
alleles, followed until death.
Error bars represent SEM.
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Promoting Their Progression into Advanced Tumors
Because Boc regulates DNA damage, we next investigated the
effects of Boc inactivation on the incidence of Ptch1 LOH, a crit-
ical event in the progression of preneoplasia into advanced MB
(Berman et al., 2002; Oliver et al., 2005; Pazzaglia et al., 2006;
Uziel et al., 2005). In early MB tumors (P30), 42% (5/12) of the
Boc+/+;Ptch1+/ mice had no Ptch1 expression in their tumor
cells (Figure 6A). In contrast, robust expression of the WT
Ptch1 allele could be detected in early MB cells from almost all
Boc/;Ptch1+/ mice (9/10; 90%). These results suggest that
Boc promotes Ptch1 LOH while the absence of Boc prevents
Ptch1 LOH in early MB, an event likely driven by the high levels
of DNA damage observed in presence of Boc.
Approximately 21% of Boc/;Ptch1+/ mice develop
advanced MB (Figure 3A). As the loss of the second allele of
Ptch1 is a common event in the progression from preneoplasia
to advanced MB, we assessed whether these advanced tumors
have also lost expression of Ptch1. Our results indicate that,
similarly to Boc+/+ tumors (8/8; 100%), the majority of Boc/Devetumors (14/16; 88%) that progress to an aggressive stage have
also lost expression of Ptch1 (Figure 6B). This contrasts with
what we observed at earlier stages (Figure 6A). Thus, the inacti-
vation of Boc reduces the probability that a tumor undergoes
Ptch1 LOH, and we suggest that this is why Boc/;Ptch1+/
mice are less prone than Boc+/+;Ptch1+/ mice to develop
advanced MB. However, in the subset of cases where LOH oc-
curs in Boc/;Ptch1+/ mice, tumors do proceed to an
advanced stage.
Interestingly, the differences in CyclinD1 and N-Myc ex-
pression that were observed between Boc/;Ptch1+/ and
Boc+/+;Ptch1+/ tumors at early MB stages were not observed
in advanced tumors (Figures 6C and 6D). These results indicate
that the genetic events that occur during the transition from
preneoplasia to advanced MB remove the dependence on Boc
for Shh signaling and proliferation. As Boc acts in Shh reception,
this is consistent with advanced MB losing Ptch1 expression,
which results in a bypass of the Shh receptor requirement.
Finally, to further confirm that Boc is important for tumor pro-
gression from preneoplasia to neoplasia but is dispensable oncelopmental Cell 31, 34–47, October 13, 2014 ª2014 Elsevier Inc. 43
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Figure 7. Boc Promotes MB Progression
from a Preneoplastic to an Advanced Stage
(A) In presence of Boc. Boc upregulation increases
Shh signaling pathway activity in early MB, and
Boc expression is also positively regulated by the
Shh signaling pathway. Thus Boc participates in a
positive feedback loop increasing Shh signaling.
This positive feedback loop promotes the
expression of Gli target genes known to stimulate
proliferation. In addition, Boc, through elevated
Shh signaling, promotes high levels of DNA
damage, an effect mediated by CyclinD1.
Elevated DNA damage increases the incidence of
Ptch1 LOH.
(B) After Ptch1 LOH has occurred, the absence of
Smo repression due to loss of Ptch1 induces
constitutive and ligand-independent expression of
Gli target genes, leading to tumor progression to
an advanced stage. These advanced tumors are
Boc-independent.
(C) In absence of Boc, the positive feedback loop
is disrupted. This results in lower proliferation and
DNA damage compared to when Boc is present.
Consequently, the frequency of Ptch1 LOH is
reduced. Mice escaping Ptch1 LOH will not
develop advanced MB.
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Boc Promotes Medulloblastoma Progressiona tumor has progressed to an advanced stage, we tested the ef-
fect of Boc inactivation in a model of advanced MB that does not
require the LOH of Ptch1 to activate Smo. For this, we used
the Math1-cre;SmoM2 mice (that harbor a constitutively active
Smo in GCPs) to generate Math1-cre;SmoM2;Boc+/+, Math1-
cre;SmoM2;Boc+/, and Math1-cre;SmoM2;Boc/ mice. We
performed a survival analysis of these mice and also confirmed
that all mice died of a MB at autopsy. The median survival be-
tween these three groups of mice were not significantly different
(Boc+/+ = 25.5 days; Boc+/ = 26 days; Boc/ = 22 days; Fig-
ure 6E), indicating that inactivation of Boc in MBs having consti-
tutive Smo activity does not decrease tumor growth, as it did in
Ptch1+/ mice (Figure 3A). Thus, in an advanced tumor model
that does not require Ptch1 LOH, the presence or absence of
Boc has no effect on tumor growth. Together with our experi-
ments showing that Boc does not affect preneoplasia formation
but promotes the LOH of Ptch1 in preneoplasia, these results
further confirm that Boc is important for tumor progression
from preneoplasia to advanced MB but is dispensable once a
tumor has progressed to an advanced stage.
DISCUSSION
Boc Promotes MB Progression from a Preneoplastic to
an Advanced Stage
Here, we report that the tissue-restricted Shh receptor Boc is
highly expressed in human and mouse MBs with activated
Shh signaling. Complementary to our findings, a genome-wide44 Developmental Cell 31, 34–47, October 13, 2014 ª2014 Elsevier Inc.screen for Gli1 transcriptional targets
identified Boc as a target of Gli1 (Lee
et al., 2010). These results indicate that
Boc expression is positively regulated
by the Shh pathway. Together with ourexperiments showing that upregulation of Boc in normal GCPs
stimulates Shh signaling and stimulates GCP proliferation in a
Shh signaling-dependent manner, these results demonstrate
that Boc participates in a positive feedback loop with Shh stim-
ulating Boc expression that further enhances Shh signaling
(Figure 7A).
We found that Boc is expressed at high levels in early pre-
neoplasia and that high Boc expression was associated with
cells having high levels of Shh signaling and high levels of pro-
liferation. Boc inactivation in preneoplasia led to a decrease in
Shh signaling and a decrease in proliferation. Furthermore, we
showed that while Boc is not involved in preneoplasia initiation,
it is important for the progression of preneoplasia into
advanced MB.
Mechanistically, our data indicate that Boc is required for Shh-
dependent DNA damage in preneoplasia (Figures 7A and 7B),
which results from the high level of Shh signaling and prolifera-
tion when Boc is present. This DNA damage is dependent on
the Shh signaling target CyclinD1. Eventually, the DNA damage
induced by Boc leads to Ptch1 LOH, a critical event required
for tumor progression from preneoplasia to advanced MB. It is
of interest that Boc, by inducing high proliferation leading to
DNA damage, causes the demise of its own coreceptor Ptch1.
As a consequence of Ptch1 LOH, the advanced tumor cells no
longer require Shh for their proliferation and thus also lose their
dependence on Boc. However, Boc expression remains high in
advanced MB because it is a transcriptional target of the Shh
pathway.
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Boc Promotes Medulloblastoma ProgressionConversely, in preneoplasia lacking Boc (Figure 7C), the level
of Shh signaling is reduced and the level of proliferation is lower.
Only low levels of DNA damage are present in these preneopla-
sia and thus the frequency of the loss of the WT allele of Ptch1 is
reduced. As a consequence, fewer preneoplasia progress to
advanced MB, explaining the higher survival observed in Boc
mutant mice compared to Boc WT mice.
In addition to the experiments mentioned above, three other
sets of experiments demonstrate that the main role of Boc is at
the progression from preneoplasia to advanced MB. First, we
observed no difference in the number of preneoplasia arising in
presence or absence of Boc, indicating that Boc does not play
a role in preneoplasia initiation. Second, in advanced tumors,
the presence or absence of Boc does not affect Shh pathway
target gene expression nor DNA damage, while it does in pre-
neoplasia. Third, we showed that inactivation of Boc inMBs hav-
ing constitutive Smo activity does not decrease tumor growth,
indicating that in an advanced MB (that has bypassed Ptch1
LOH), the presence or absence of Boc has no effect on tumor
growth. Altogether, these results indicate that Boc plays an
important role for tumor progression but is dispensable once a
tumor has progressed to an advanced stage.
BOC Genomic Gain and Amplification
At the genomic level, we found that a chromosomal region
containing the BOC gene can be gained in human MB of the
SHH subgroup and that MB tumors from Li-Fraumeni patients
can have high-level amplifications of BOC. In light of our results
showing that BOC upregulation can increase cell proliferation,
genomic amplification of BOC, through the subsequent in-
creased expression of BOC, might be an additional genetic
event that can cooperate with other genes to further drive the
proliferation of tumor cells. Alternatively, BOC could potentially
be a MB driver and be sufficient to form MBs. However, as we
found that BOC overexpression in GCP progenitors is not suffi-
cient to initiate MB tumorigenesis (Figure S5), this suggests that
BOC amplification might need to collaborate with other genetic
events to induce MB, such as Ptch1+/. Furthermore, our obser-
vation that BOC cannot initiate MB on its own is consistent with
a lack of a role for BOC in preneoplasia formation and further
supports its role in the progression from preneoplasia to
neoplasia. Of interest, Boc is not the only gene that acts in the
progression from preneoplasia to neoplasia in MB. Similarly,
N-Myc overexpression alone is not sufficient to induce MB,
but N-Myc increases the frequency of MB formation in combina-
tion with other Shh activation mechanisms such as Shh overex-
pression (Browd et al., 2006) or inactivation of Ptch1 (Kessler
et al., 2009). Studying larger human SHH-MB cohorts will help
identify genetic events that collaborate with BOC gain and
amplification.
Boc and DNA Damage
Some oncogenes, in addition to inducing high proliferation, also
induce DNA replication stress (Bartkova et al., 2005; Gorgoulis
et al., 2005). Oncogene-induced DNA replication stress can
lead to the acquisition of DNA damage and mutations necessary
for cancer progression fromapreneoplastic to a neoplastic stage
(Bartkova et al., 2005; Gorgoulis et al., 2005). We have demon-
strated that Boc is essential for Shh-induced DNA damage andDevealso regulates the levels of CyclinD1, an oncogene capable of
promoting replication stress in other cell types (Aggarwal et al.,
2007). We have also demonstrated that Shh-induced DNA dam-
age requires CyclinD1. Thus, it is possible that Boc mediates
tumor progression through a CyclinD1-dependent replication
stress and DNA damage mechanism. However whether Boc-
inducedDNAdamage is dependent on replication stress remains
to be proven. Nonetheless, the importance of Boc in regulating
DNAdamage is underscoredbyour results showing that inactiva-
tion of Boc completely abrogates Shh-inducedDNAdamage and
significantly reduces Ptch1 LOH and the subsequent mortality
associated with advanced MBs.
Differential Mechanisms for Hog Family Members
in Cancer
The Hog family members (Boc and Cdon in vertebrates and iHog
and Boi in invertebrates) play important roles in normal develop-
ment as essential coreceptors required for Hh signaling (Allen
et al., 2011; Camp et al., 2010; Izzi et al., 2011; Zheng et al.,
2010). Cdon has recently been reported to also be a dependence
receptor inducing apoptosis in absence of Shh (Delloye-Bour-
geois et al., 2013). The authors propose that Shh expression in
cancer cells provides a selective tumor growth advantage by
blocking Cdon-induced apoptosis. However, unlike Cdon, Boc
does not function as a dependence receptor (Delloye-Bourgeois
et al., 2013), consistent with our data showing no difference in
apoptosis levels in Boc/ versus Boc+/+ mice. Thus, unexpect-
edly, our results demonstrate that the tumorigenesis mechanism
promoted by Boc inMB is distinct to the one described for its ho-
molog Cdon. Notably, although Boc and Cdon have highly ho-
mologous extracellular domains, their intracellular domains
show little homology (Kang et al., 2002). For Cdon, it is the pro-
teolytic cleavage of its intracellular domain that recruits and ac-
tivates caspase-9 and allows it to trigger apoptosis. Hence the
ability of Cdon, but not Boc, to function as a dependence recep-
tor may be specific to its intracellular domain. Thus the differen-
tial expression of Boc and Cdon in different tissues could
contribute to distinct mechanisms via which Shh signaling can
promote tumorigenesis.
EXPERIMENTAL PROCEDURES
See the Supplemental Information for additional procedures.
Mouse Lines
All animal work was performed in accordance with Canadian Council on An-
imal Care guidelines. Boc (Okada et al., 2006) and Ptch1 (Goodrich et al.,
1997) mice were backcrossed with C57BL/6 mice (Harlan) for at least six
generations. Math1-Cre;SmoM2 mice were generated by crossing Math1-
Cre (D. Rowitch) with SmoM2 mice (Jeong et al., 2004). CyclinD1 mice
were previously described (Sicinski et al., 1995) and were a kind gift from
P. Jolicoeur.
MB Frequency in Ptch1+/– Mice
Ptch1+/ mice (Goodrich et al., 1997) were backcrossed in a C57BL/6 back-
ground (Harlan) for over six generations. In our colony, we routinely observe
that 55% of the Ptch1+/ mice develop MB. At least four other groups
have reported a MB incidence higher than the originally reported incidence
of 15%–20% for the Ptch1+/ mice, with incidences close or equal to the
55% incidence that we report in our manuscript (Ayrault et al., 2009; Lee
et al., 2010; Sva¨rd et al., 2009; Wu et al., 2012).lopmental Cell 31, 34–47, October 13, 2014 ª2014 Elsevier Inc. 45
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Boc Promotes Medulloblastoma ProgressionHistology, Immunohistochemistry, and Immunofluorescence
Animals were anesthetized using Ketamine/Xylazine and perfused with 4%
paraformaldehyde (PFA). Whole cerebella were dissected, postfixed, and
cryoprotected according to standard protocols. Immunohistochemistry and
immunofluorescence were performed as previously described (Charron
et al., 2003; Fabre et al., 2010; Okada et al., 2006) using goat anti-Boc (R&D
Systems), goat anti-Cdon (R&D Systems), rabbit anti-b-galactosidase (MP
Biomedicals), mouse anti-CyclinD1 (Santa Cruz), rabbit anti-g-H2AX (Cell
Signaling), mouse anti-Ki67 (BD PharMingen), and rabbit anti-active cas-
pase-3 (Cell Signaling) antibodies. All cerebella were cut into 12 mm thick
sagittal sections except for Figures 3C–3E (200 mm).
Microscopy
Fluorescence and brightfield images were acquired with Leica DM6000 and
DM4000 microscopes with an Orca ER CCD camera (Hamamatsu) using Vo-
locity (Improvision). A Zeiss LSM 710 confocal microscope was used to image
experiments requiring fluorescence colocalization.
Isolation of GCPs
GCPswere isolated frommouse cerebella using amodified protocol (Izzi et al.,
2011). GCPs were resuspended in Neurobasal supplemented with B27
(GIBCO), 0.5 mM L-glutamine (GIBCO) and penicillin/streptomycin. P7 GCPs
were seeded at 2 3 105 cells/well in 24-well plates (DNA damage analysis),
5 3 105 cells/well in 24-well plates (Comet assay), 1 3 106 cells/well in
6-well plates (mRNA expression analysis), all precoated with 100 mg/ml poly-
D-lysine (Sigma). GCP cell pellets and MB cell pellets from 4-week-old mice
were directly resuspended in lysis buffer for mRNA expression analysis.
RNA Purification and Quantitative RT-PCR
RNA was purified using the RNeasy Mini Plus kit (QIAGEN). cDNA was synthe-
sized using the Transcriptor first strand cDNA synthesis kit (Roche) using total
RNA.Real-timePCRmixeswerepreparedusingPerfectaSYBRGreenSupermix
(Quanta Biosciences). Results were analyzed using the ComparativeCt method.
Human Tumor Samples and Expression Analysis
RNA isolated from 64 (Heidelberg) and 103 (Toronto) medulloblastoma sam-
ples were hybridized respectively to the 4x44K feature Agilent Whole Human
Genome (Gene Expression Omnibus [GEO], accession number GSE28245)
(Remke et al., 2011) or to the Affymetrix Genechip Human Exon 1.0 ST arrays
(GEO, accession number GSE21140) (Northcott et al., 2011).
500K SNP Array
Copy-number variant data were generated on primary medulloblastoma sam-
ples using the Affymetrix 500K single-nucleotide polymorphism (SNP) array
platform and analyzed as described (Northcott et al., 2009).
Infection and Electroporation of GCPs
GCPs were infected with pCLE or pCLE-BOC retrovirus or were electropo-
rated with pEGFP or pEGFP-Boc expressing plasmids using an Amaxa sys-
tem. See Supplemental Experimental Procedures for details.
Comet Assay
Isolated GCPs cultured for 18 hr in 10 nM ShhN were resuspended in low
melting point agarose (Invitrogen) and processed for comet assays. See
Supplemental Experimental Procedures for details.
Statistical Analysis
Unless otherwise noted, all data are expressed as mean ± SEM and were
analyzed using Prism 5 (GraphPad). Statistical significance is: *p < 0.05;
**p < 0.01; ***p < 0.001; n.s., not significant.
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